ABSTRACT: Dysregulation of cathepsin B, which involves the translocation of the enzyme from acidic pH lysosomes to the neutral pH cytosol, followed by the initiation of cell death and inflammation, occurs in numerous brain disorders. The wide difference in the acidic pH (4.6) of lysosomes compared to the neutral pH (7.2) of the cytosol suggests that screening at different pH conditions may identify pH-selective modulators of cathepsin B. Therefore, a collection of pure marine and plant natural product (NP) compounds, with synthetic compounds, was screened at pH 4.6 and pH 7.2 in cathepsin B assays, which led to the identification of GER-12 (Crossbyanol B) and GER-24 ((7Z,9Z,12Z)-octadeca-7,9,12-trien-5-ynoic acid) marine NP inhibitors at acidic pH but not at neutral pH. GER-12 was effective for the reversible inhibition of cathepsin B, with an IC₅₀ of 3 μM. GER-24 had an IC₅₀ of 16 μM and was found to be an irreversible inhibitor. These results show that NP screening at distinct biological pH conditions can lead to the identification of pH-selective cathepsin B modulators. These findings suggest that screening efforts for molecular probes and drug discovery may consider the biological pH environment of the target in the disease process.

INTRODUCTION

Cathepsin B is a lysosomal cysteine protease that is normally involved in molecular pathways that maintain cellular homeostasis through proteolysis and protein catabolism. Dysregulation of cathepsin B has been implicated in brain disorders, including Alzheimer’s disease (AD), traumatic brain injury (TBI), and others, as well as cancer and inflammatory diseases. The inhibition of cathepsin B activity has been an area of interest to assess the mechanistic role of cathepsin B in disease pathogenicity and drug discovery efforts.

Evidence for the participation of cathepsin B in brain disorder pathogenicity has spurred much investigation into agents that inhibit cathepsin B to ameliorate dysfunctions associated with neurodegenerative diseases. Cathepsin B is involved in the inflammatory pathways and cell death pathways of AD and TBI, which are hypothesized to involve the leakage of lysosomal cathepsin B into the cytosol. In vivo inhibition or gene silencing of cathepsin B in AD mouse models results in improved memory deficits and alleviates neuropathology. In vivo studies of TBI mouse models show that gene knockout of cathepsin B improves motor dysfunction and reduces brain tissue loss. Furthermore, clinical patient studies indicate elevated levels of cathepsin B in AD and TBI. Thus, there is interest in the field to discover new cathepsin B inhibitors.

Marine and plant natural products (NP) provide rich sources of chemically diverse compounds that are biologically active and useful as active therapeutic agents. Studies have shown that potent and effective protease inhibitors can be identified from NP sources. For example, gallinamide A is a potent and selective inhibitor of the lysosomal cysteine protease cathepsin L discovered from marine cyanobacteria, which has the potential to reduce SARS-CoV-2 infection. Natural products, both marine and terrestrial, account for ~50% of small-molecule drugs approved for the treatment of cancer and related conditions; this includes their novel structures as well as their derivatives. Thus, NP small-molecule libraries provide rich and novel resources to search for selective inhibitors of cathepsin B activity.

Screening of small molecules in drug discovery efforts has traditionally utilized optimal enzyme assay conditions for the assessment of effective modulators. However, drug targets in biological systems may be located at different pH conditions compared to normal healthy conditions. For example, cathepsin B in numerous brain disorders and cancer mediates disease deficits at abnormal neutral pH locations, including the cytosol and extracellular locations; however, cathepsin B is normally located in lysosomes containing an acidic internal environment.
pH. The large pH differences between pathogenic and normal enzyme locations in biological systems suggest that drug discovery should target the pathogenic pH form of the enzyme in screening programs.

Significantly, our previous studies showed that cathepsin B is selectively inhibited by Z-Arg-Lys-AOMK at neutral pH 7.2 with a nanomolar (nM) potency, with no inhibition at acidic pH 4.6 at nM inhibitor concentrations. The Z-Arg-Lys-AOMK inhibitor was designed using the pH 7.2 preferences of residues adjacent to the cleavage sites of cathepsin B proteolysis. Cleavage profiling analysis of cathepsin B using a defined library of diverse peptide substrates led to the design of the neutral-pH-selective substrate Z-Arg-Lys-AMC and an acid-pH-selective substrate Z-Glu-Lys-AMC. We propose that the use of these pH-selective substrates in compound screening efforts may uncover pH-selective modulators of cathepsin B.

For these reasons, the goal of this study was to evaluate the hypothesis for differential screening outcomes of natural product (NP) modulators, from marine and plant organisms, of cathepsin B by comparing screening assays conducted at the acidic lysosomal pH of 4.6 to those conducted at the neutral cytosolic pH of pH 7.2. Indeed, results of such a screening approach identified NP inhibitors effective at acidic pH, but not at neutral pH, for inhibition of cathepsin B. These findings indicate that NP compound screening at distinct biological pH conditions can lead to the differential identification of cathepsin B enzyme modulators. Furthermore, the finding of pH-dependent NP modulators may reflect natural pH-dependent activities of NP molecules in their native ecological environments.

## Results and Discussion

**Results. Strategy to Assess Marine and Plant Natural Product (NP) Modulators of Cathepsin B at Acidic and Neutral pH Conditions Using pH-Selective Peptidic Substrates.** A collection of purified natural product compounds consisting of 151 chemical molecules from marine organisms of cyanobacteria, Rhodophyta, sponge, mollusk, and Phaeophyceae combined with NP molecules from plants were utilized to discover pH-dependent inhibitory modulators of human cathepsin B proteolytic activity (Figure 1). Our unique cathepsin B screening strategy was conducted at the lysosomal pH of 4.6 and the cytosolic pH of 7.2. These cathepsin B assays used pH-selective substrates Z-Glu-Lys-AMC and Z-Arg-Lys-AMC that monitor cathepsin B activity at acidic pH 4.6 and neutral pH 7.2, respectively. NP molecules displaying at least 50% inhibition of cathepsin B activity were further assessed for potency by calculating IC_{50} values, the reversible or irreversible mechanism of inhibition, and the specificity of the NP inhibition of cathepsin B compared to other cysteine cathepsins.

**Inhibitors of Acidic Cathepsin B Activity Revealed through Screening a Collection of Pure NP Compounds at Neutral and Acidic pH Assay Conditions.** The library of pure NPs from marine and plant organisms was assessed for the modulation of human cathepsin B activity. Assays were conducted by preincubating (30 min) each NP with cathepsin B at pH 7.2 and pH 4.6, followed by adding the substrate and monitoring the proteolytic activity. Screening of the NP compounds utilized pH-selective substrates Z-Arg-Lys-AMC at pH 7.2 and Z-Glu-Lys-AMC at pH 4.6, which led to the identification of several active compounds that showed varying degrees of cathepsin B modulation (Figure 2). Seven compounds were observed to significantly (p < 0.05) inhibit cathepsin B activity at pH 4.6 by at least 50% at NP concentrations of 1–10 μM, with no inhibition of cathepsin B at neutral pH 7.2 (Table 1). Furthermore, at pH 4.6, one NP molecule activated cathepsin B at least 200% or greater compared to controls (100%), with no effects at pH 7.2. Additionally, two other NPs activated cathepsin B at pH 7.2 without effects at pH 4.6 (Table 1). These results illustrate the differential discovery of NP inhibitors or activators of cathepsin B activity at acidic pH 4.6 compared to neutral pH 7.2. Inhibition of cathepsin B has been predicted in the field to ameliorate several conditions of brain disorders, cancer, infectious disease, and others. Therefore, we continued with the characterization of NP inhibitors of cathepsin B.
Table 1. Identification of pH-Selective Marine Natural Product Modulators of Cathepsin B

| Natural Product Compound | Concentration | Cathepsin B Activity | Compound Structure |
|-------------------------|---------------|-----------------------|--------------------|
|                         |               | pH 4.6 Z-E-K-AMC      | pH 7.2 Z-R-K-AMC   |
| None                    | 0             | 100%                  | 100%               |
| GER-12                  | 1.6 μM (2 μg/ml) | 43 ± 5 *             | 78 ± 15            |
| GER-24                  | 8.0 μM (2 μg/ml) | 23 ± 1 *             | 117 ± 5            |
| GER-151                 | 5.2 μM (2 μg/ml) | 205 ± 21 *           | 109 ± 11           |
| GER-163                 | 2.2 μM (2 μg/ml) | 48 ± 7 *             | 118 ± 11           |
| GER-165                 | 8.6 μM (2 μg/ml) | 47 ± 4 *             | 120 ± 13           |
| GER-169                 | 4.4 μM (2 μg/ml) | 38 ± 7 *             | 128 ± 7            |
| GER-170                 | 6.0 μM (2 μg/ml) | 50 ± 4 *             | 118 ± 3            |
| ST024730                | 2.0 μM        | 50 ± 7 *             | 173 ± 33           |
| ST024752                | 2.0 μM        | 111 ± 33             | 241 ± 21 *         |
| ST024772                | 2.0 μM        | 73 ± 22              | 205 ± 21 *         |

* A collection of pure marine natural products (purified) were assessed for the modulation of human cathepsin B activity (with preincubation) by screening them at pH 4.6 and pH 7.2 using pH-selective substrates of Z-E-K-AMC and Z-R-K-AMC, respectively. The asterisk indicates compounds that resulted in a significant inhibition of <50% (blue) or activation of >200% (green) with *p < 0.05.

GER-12 (Crossbyanol B) and GER-24 ((7Z,9Z,12Z)-Octadeca-7,9,12-trien-5-ynoic Acid) NP Inhibition of Cathepsin B at Acidic pH. To evaluate the seven inhibitors at the same concentration, inhibitors were tested at 5 μM since the initial inhibitor testing was performed in the micromolar range (shown in Table 1). Reassessment of the seven inhibitors (without preincubation) resulted in two compounds, GER-12 and GER-24, that demonstrated the inhibition of cathepsin B (Table 2). Therefore, continued studies examined GER-12 and GER-24 in concentration-dependent studies (Figures 3 and 4, respectively).

The potencies of the NPs were assessed by calculating the concentration of each compound that inhibited cathepsin B by 50% (IC_{50} value). The GER-12 inhibition of cathepsin B at pH
4.6 had an IC₅₀ value of 3 μM (Figure 3b). The GER-24 inhibition of cathepsin B at pH 4.6 had an IC₅₀ value of 16 μM (Figure 4b). These results show the effective inhibition of cathepsin B at acidic pH by GER-12 and GER-24 at micromolar levels of inhibitors.

GER-12 reversible inhibition and GER-24 irreversible inhibition of cathepsin B. The mechanism of GER-12 and GER-24 inhibition was assessed by preincubating cathepsin B (at 100X the enzyme concentration for the assay) for 30 min with the inhibitor (at 10X times its IC₅₀). A 100-fold dilution was then performed on the mixture, and the Z-E-K-AMC substrate was added to the mixture to monitor the proteolytic activity over a time-course up to 120 min.

After GER-12 preincubation, the progress of cathepsin B activity in the time course was similar to that for the enzyme incubated alone (no inhibitor), demonstrating reversible inhibition by GER-12 (Figure 3c). Further assessment of the reversible inhibition showed that GER-12 inhibition of cathepsin B was not observed in the presence of the nonionic detergent triton X-100 (Supplemental Figure S1).

After GER-24 preincubation, cathepsin B inhibition occurred over the entire time course, which demonstrated the irreversible inhibition of cathepsin B by GER-24 (Figure 4c). These data demonstrate the different reversible and irreversible inhibition mechanisms of GER-12 and GER-24, respectively.

Kinetics of GER-12 and GER-24 inhibition. Kinetics of GER-12’s reversible inhibition of cathepsin B was assessed by Michael–Menten and inverse Lineweaver–Burk plots (Supplemental Figure S2). A Kᵢ value of 1.4 μM was calculated for the noncompetitive inhibition of cathepsin B by GER-12. GER-24’s irreversible inhibition of cathepsin B was observed to possess the kinetic constant kₐ∕kᵢ of 4.2 × 10⁵ μM⁻¹ s⁻¹ (Supplemental Figure S3).

GER-12 and GER-24 inhibition of cathepsin B compared to other cysteine cathepsins. GER-12 was evaluated for the inhibition of cathepsin B compared to members of the cysteine cathepsin family consisting of cathepsins C, H, K, L, S, V, and X. At 10 μM (pH 4.6), GER-12 inhibited cathepsin B up to 14% of the control with no inhibitor (100%) and inhibited cathepsins C, H, K, L, S, V, and X up to 26%, 8%, 21%, 89%, 13%, 3%, and 54% compared to control (Table 3). These data indicate that GER-12 inhibits several cysteine cathepsins in addition to cathepsin B.

At 50 μM (pH 4.6), GER-24 inhibited cathepsin B up to 0% of control (100%) and inhibited cathepsins C, H, K, L, S, V, and X up to 65% 21%, 7%, 84%, 0%, 17%, and 67% compared to the no-inhibitor control (100%) (Table 3). Thus, GER-24 at a high concentration of 50 μM inhibits cathepsin B and several cysteine cathepsin proteases.

These data show that the inhibition of cathepsin B by GER-12 and GER-24 occurs without selectivity, as shown by inhibition of other cysteine cathepsin proteases.

**DISCUSSION**

Results of this study highlight the incorporation of biological pH conditions for screening NP modulators of cathepsin B at acidic pH compared to neutral pH conditions. The use of different pH screening conditions for cathepsin B resulted in the identification of different NP compounds that inhibited cathepsin B at lysosomal acidic pH 4.6 compared to cytosolic neutral pH 7.2. These findings indicate the importance of considering the distinct pH environments of the biological locations of enzyme targets in the design of screening conditions to identify NP or other types of chemical modulators. Most chemical library screens for enzyme modulators utilize the optimum in vitro enzymatic assay conditions, including pH. However, differential pH properties of enzymes, such as those for cathepsin B, suggest that the target enzyme may be treated as distinct types of enzymes at different pH levels. Our previous finding of pH-selective modulators of cathepsin B may reflect the enzyme’s pH-selective cleavage properties at acidic and neutral pH conditions.¹⁹ The discovery and development of modulators through chemical screening will benefit from specifying the pH.
Proteases such as cathepsin B may have dual functions within acidic lysosomes and extra-lysosomal neutral cellular compartments, including the cytosol, nuclei, and extracellular locations.\(^1\)\(^2\)\(^3\) Cathepsin B, for example, displays distinct substrate and inhibitor specificity at acidic pH compared to neutral pH functions.\(^1\)\(^9\)\(^2\)\(^4\) Therefore, it will be valuable to develop inhibitors of neutral pH cathepsin B to allow the assessment of its functions in extra-lysosomal locations, including cell death, inflammation, and cancer. Selective inhibitors of acidic cathepsin B functions will enhance the understanding of the enzyme’s role in protein health, namely proteostasis, which is important for cellular functions in health and disease. Furthermore, pH-selective activators may be utilized to gain an additional understanding of the function of cathepsin B.

Furthermore, the results of our NP screens for modulators of cathepsin B indicate that marine natural product molecules such as GER-12 (crossbyanol B from cyanobacteria) and GER-24 ((7\(^\text{Z},9\text{Z},12\text{Z})\text{-octadeca-7,9,12-trien-5-ynoic acid from Rhodophyta}) may possess pH-dependent modulating functions for target enzymes. This study opens avenues to assess natural products for the pH-selective inhibition or activation of proteases and enzymes. Therefore, natural product screening under different biological pH conditions, as demonstrated by this study, can be an important avenue to advance our understanding of the multiple roles of cathepsin B and enzymes in cellular compartments of differing pH conditions.

In summary, the results of this study indicate that using different pH conditions to screen NP chemical libraries can lead to the identification of pH-selective modulators of targeted protease enzymes in designated biological pH environments.

### EXPERIMENTAL PROCEDURES

Experimental procedures are summarized here. Detailed descriptions of protocols are provided in the Supporting Information.

**Materials and Reagents.** The sources of enzymes, peptide substrates, and reagents are provided in the Supporting Information.

**Collection of Purified Marine and Plant Natural Products (NP).** Natural products have been collected and purified from multiple marine organisms of cyanobacteria, Rhodophyta, sponges, mollusk, Phaeophyceae, and plant sources. The list of NP molecules investigated is provided in Supporting Information Table S1. Marine NP compound stocks were 1 mg/mL and were screened at a final concentration of the enzyme target to address pH-specific cellular or physiological functions.

It is of interest that cathepsin B displays pH-dependent properties for inhibitors through compound screening at acidic pH 4.6 and neutral pH 7.2 conditions. Protease inhibitors often mimic peptide substrate-binding properties with the protease enzyme. The substrate profiling analysis of cathepsin B showed its pH-dependent preferences for amino acid residues adjacent to the P1–P1’ substrate cleavage sites.\(^1\)\(^9\) Notably, glutamate (Glu) is the preferred P2 residue of cathepsin B at acidic pH 4.6, but the Glu residue is not preferred at pH 7.2. It is of interest that GER-24 possesses a functional group of \(-\text{CH}_2\text{-CH}_2\text{-COOH}\) that resembles the Glu side chain of substrates that interact with the S2 subsite (Glu-245) of the enzyme.\(^1\)\(^9\) Thus, it is possible that the \(-\text{CH}_2\text{-CH}_2\text{-COOH}\) group of GER-24 may interact with cathepsin B at its S2 subsite. With respect to GER-12, its inhibitory activity was not observed in the presence of the detergent triton X-100, suggesting nonionic detergent-dependent interactions; however, a future structural analysis will be needed. Interactions of inhibitors with target proteases are best assessed by structural analysis via X-ray crystallography, which has, for example, been achieved for the selective CA-074 inhibitor of cathepsin B.\(^2\)\(^0\)\(^-\)\(^2\)\(^2\) CA-074 interacts with the enzyme’s active site region at the S2–S2’ subsites. It will be of interest to assess pH-selective inhibitor interactions with cathepsin B through future structural analyses.

| protease  | GER-12 (10 \(\mu\)M) % control activity (100%, no inhibitor) | GER-24 (50 \(\mu\)M) % control activity (100%, no inhibitor) |
|-----------|-------------------------------------------------------------|-------------------------------------------------------------|
| cathepsin B | 14 (no inhibitor) | 0 (no inhibitor) |
| cathepsin C | 26 (no inhibitor) | 65 (no inhibitor) |
| cathepsin H | 8 (no inhibitor) | 21 (no inhibitor) |
| cathepsin K | 21 (no inhibitor) | 7 (no inhibitor) |
| cathepsin L | 89 (no inhibitor) | 84 (no inhibitor) |
| cathepsin S | 13 (no inhibitor) | 0 (no inhibitor) |
| cathepsin V | 3 (no inhibitor) | 17 (no inhibitor) |
| cathepsin X | 53 (no inhibitor) | 67 (no inhibitor) |

GER-12 and GER-24 inhibition (no preincubation) of cathepsin B and the cysteine cathepsins C, H, K, L, S, V, and X were compared. Assay conditions (no preincubation) for these human cysteine cathepsins are provided in the procedures.

**Supporting Information Table S1.** Marine NP compound stocks were 1 mg/mL and were screened at a final concentration of the enzyme target to address pH-specific cellular or physiological functions.

**Figure 4.** GER-24 ((7\(^\text{Z},9\text{Z},12\text{Z})\text{-octadeca-7,9,12-trien-5-ynoic acid}) potency and irreversible inhibition of cathepsin B. (a) The GER-24 NP structure, (b) the potency for inhibition illustrated by its IC\(_{50}\) value, and (c) the irreversible mechanism of inhibition are illustrated. Potency was assessed at different concentrations of GER-12 for the inhibition of cathepsin B, as assessed by the IC\(_{50}\) value, and the irreversible mechanism of GER-12 inhibition was determined by dilution experiments, as explained in the section Experimental Procedures.
concentration of 2 μg/mL. The plant NP compounds stocks were at 1 mM and were screened at a final concentration of 2 μM. The structures of the NP molecules are provided in Supporting Information Table S2, which indicates diverse NP chemical structures. These molecules were utilized for screening in the cathepsin B assays.

**NP Screening Conducted at pH 4.6 and pH 7.2 to Identify Modulators of Cathepsin B.** Assays of cathepsin B (activated) with 151 pure marine natural products were conducted in triplicate with 5 mM DTT, 1 mM EDTA, 100 mM NaCl, and 1.5% DMSO using 0.2 ng/μL cathepsin B at pH 4.6 in 40 mM citrate phosphate buffer with 60 μM Z-Glu-Lys-AMC substrate and at pH 7.2 in 40 mM citrate phosphate buffer with 60 μM Z-Arg-Lys-AMC substrate. Each pure NP (151 compounds in total) was preincubated with the enzyme for 30 min at RT. To the mixture was then added the substrate, and the sample was incubated at RT for 30 min. Fluorescence was measured at 360 nm excitation and 460 nm emission. Cathepsin B activity in the absence and presence of each NP was assessed for significance using Student’s t test with p < 0.05. As a positive inhibitor control, each screening plate included CA-074 (1 μM final concentration), a known selective inhibitor of cathepsin B.

**Potency of NP Inhibition of Cathepsin B as Assessed by IC₅₀ Values.** GER-12 (crossbyanol B) and GER-24 (7Z,9Z,12Z-octadeca-7,9,12-trien-5-ynoic acid) at different concentrations were incubated with cathepsin B (activated) without preincubation in cathepsin B assay conditions (described above). IC₅₀ values were calculated as the inhibitor concentration that reduced cathepsin B activity by 50%. Curve-fitting of the inhibition curves and the calculation of IC₅₀ values were performed with Prism software (version 8). Confidence intervals of 95% were obtained for GER-24 and GER-12 at 7.9–36.5 and 2.1–4.4 μM, respectively, using a nonlinear regression curve fit model.

**Assessment of Inhibitors for a Reversible or Irreversible Mechanism of Inhibition.** Cathepsin B (100X) was preincubated with GER-12 or GER-24 at 10X the determined IC₅₀ concentration for 30 min at room temperature (25 °C). Then, a 1:100 dilution of the mixture was performed. The Z-Glu-Lys-AMC substrate was added to the diluted mixture, and the fluorescence was monitored for proteolytic activity every minute for 2 h. The lack of inhibition of cathepsin B activity following dilution indicates a reversible inhibitory mechanism. The reduction of cathepsin B activity following dilution indicates an irreversible inhibitory mechanism.

**Kinetics of the Reversible and Irreversible Inhibition of Cathepsin B.** GER-12 reversible inhibition kinetics was assessed by Michaelis–Menten and Lineweaver–Burke inverse plots to determine the Kᵢ value for the noncompetitive inhibition of cathepsin B by GER-12 using the equation: \[ V_{\text{max}} = \frac{V_{\text{max}}}{K_i/IP + K_i}. \] The irreversible inhibition by GER-24 was assessed by determining the Kᵢ value as we previously described.

**Evaluation of GER-12 and GER-24 for the Inhibition of Cathepsin B Compared to Other Cysteine Cathepsins.** GER-12 at 10 μM and GER-24 at 50 μM were evaluated for the inhibition of cathepsin B compared to cathepsins C, H, K, L, S, V, and X. Assay conditions for these cathepsin proteases are described in the Supporting Information.

**ASSOCIATED CONTENT**

**Supporting Information**

The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acsomega.2c02287.

Natural product compound library information (XLSX)

Effect of triton X-100 on GER-12 inhibition, plots of the irreversible and reversible inhibition kinetics, supplemental experimental procedures, and structures of natural products, (PDF)

**AUTHOR INFORMATION**

**Corresponding Author**

Vivian Hook – Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, California 92093, United States; Department of Neurosciences and Department of Pharmacology, School of Medicine, University of California, San Diego, La Jolla, California 92093, United States; orcid.org/0000-0001-6461-7024; Email: vhook@ucsd.edu

**Authors**

Von V. Phan – Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, California 92093, United States; Biomedical Sciences Graduate Program, University of California, San Diego, La Jolla, California 92093, United States

Charles Mosier – Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, California 92093, United States

Michael C. Yoon – Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, California 92093, United States; Biomedical Sciences Graduate Program, University of California, San Diego, La Jolla, California 92093, United States

Evgenia Glukhov – Scripps Institution of Oceanography, University of California, San Diego, La Jolla, California 92093, United States

**Conor R. Caffrey** – Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, California 92093, United States

**Anthony J. O’Donoghue** – Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, California 92093, United States; orcid.org/0000-0001-6595-0409

**William H. Gerwick** – Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, California 92093, United States; Scripps Institution of Oceanography, University of California, San Diego, La Jolla, California 92093, United States; orcid.org/0000-0003-1403-4458

Complete contact information is available at: https://pubs.acs.org/10.1021/acsomega.2c02287

**Author Contributions**

V.H. and W.H.G. designed the research project and assessed the results. E.G. prepared the natural product compounds for...
screening. V.V.P. and C.M. conducted the experiments and data calculations for analysis. A.J.O. and C.R.C. provided advice and evaluated the results. V.H. and V.V.P. wrote the manuscript text. All authors provided editorial input for the final manuscript submitted.

Notes
The authors declare the following competing financial interest(s): V.H. has an equity position at American Life Science Pharmaceuticals (ALSP) and is a founder of ALSP. V.H. is an advisor to ALSP. V.H.’s conflict has been disclosed and is managed by her employer, the University of California, San Diego. The other authors have no conflicts of interest.

ACKNOWLEDGMENTS
This research was supported by NIH Grant R01NS109075 awarded to V.H. V.V.P. was supported by NIH Grant T32GM007752. Biorender was utilized to generate the graphic awarded to V.H. V.V.P. was supported by NIH Grant R01NS109075 and is managed by her employer, the University of California, San Diego.

REFERENCES

(1) Turk, V.; Stoka, V.; Vasiljeva, O.; Renko, M.; Sun, T.; Turk, B.; Turk, D. Cysteine Cathepsins: From Structure, Function and Regulation to New Frontiers. Biochim. Biophys. Acta, Proteins Proteomics 2012, 1824 (1), 68–88.

(2) Hook, V.; Yoon, M.; Mosier, C.; Ito, G.; Podvin, S.; Head, B. P.; Rissman, R.; O’Donoghue, A. J.; Hook, G. Cathepsin B in Neurodegeneration of Alzheimer’s Disease, Traumatic Brain Injury, and Related Brain Disorders. Biochim. Biophys. Acta, Proteins Proteomics 2020, 1868 (8), 140428.

(3) Aggarwal, N.; Sloane, B. F. Cathepsin b: Multiple Roles in Cancer. Prot. Clin. Appl. 2014, 8, 427–437.

(4) Amaral, E. P.; Riteau, N.; Moayeri, M.; Maier, N.; Mayer-Barber, K. D.; Pereira, R. M.; Lage, S. L.; KUBLER, A.; BISHAI, W. R.; D’IMPERIO-Prot. Clin. Appl. Cancer. 2012, 1868 (8), 140428.

(5) Rajämäki, K.; Lappalainen, J.; Öörni, K.; Välimäki, E.; Matikainen, S.; Kovanen, P. T.; Eklund, K. K. Cholesterol Crystals Activate the NLRP3 Inflammasome in Human Macrophages: A Novel Link between Cholesterol Metabolism and Inflammation. PLoS One 2010, 5 (7), e11765.

(6) Hook, G.; Hook, V.; Kindy, M. The Cysteine Protease Inhibitor, E64d Reduces Amyloid-β and Improves Memory Deficits in Alzheimer’s Disease Animal Models by Inhibiting Cathepsin B, but not BACE1, β-Secretase Activity. JAD 2011, 26 (2), 387–408.

(7) Kindy, M. S.; Yu, J.; Zhu, H.; El-Amouri, S. S.; Hook, V.; Hook, G. R. Deletion of the Cathepsin B Gene Improves Memory Deficits in a Transgenic Alzheimer’s Disease Mouse Model Expressing AβPP Containing the Wild-Type β-Secretase Site Sequence. JAD 2012, 29 (4), 827–840.

(8) Hook, G.; Yu, J.; Toneff, T.; Kindy, M.; Hook, V. Brain Pyroglutamate Amyloid-β Is Produced by Cathepsin B and Is Reduced by the Cysteine Protease Inhibitor E64d, Representing a Potential Alzheimer’s Disease Therapeutic. JAD 2014, 41 (1), 129–149.

(9) Hook, G.; Jacobsen, J. S.; Grabstein, K.; Kindy, M.; Hook, V. Cathepsin B Is a New Drug Target for Traumatic Brain Injury Therapeutics: Evidence for E64d as a Promising Lead Drug Candidate. Front. Neurol. 2015, 6, 178.

(10) Sun, Y.; Rong, X.; Lu, W.; Peng, Y.; Li, J.; Xu, S.; Wang, L.; Wang, X. Translational Study of Alzheimer’s Disease (AD) Biomarkers from Brain Tissues in AβPP/PS1Mice and Serum of AD Patients. JAD 2015, 45 (1), 269–282.

(11) Assfalg-Machleidt, I.; Jochum, M.; Nast-Kolb, D.; Siebeck, M.; Billing, A.; Joka, T.; Rothe, G.; Valet, G.; ZAuner, R.; Scheuber, H.-P.; Machleidt, W. Cathepsin B-Indicator for the Release of Lysosomal Cysteine Proteinases in Severe Trauma and Inflammation. Biol. Chem. Hoppe Seyler 1990, 371, 211–222.

(12) Villa, F. A.; Gerwick, L. Marine Natural Product Drug Discovery: Leads for Treatment of Inflammation, Cancer, Infections, and Neurological Disorders. Immunopharmacol. Immuno toxicol. 2010, 32 (2), 228–237.

(13) Che, C.-T.; Zhang, H. Plant Natural Products for Human Health. Int. J. Mol. Sci. 2019, 20 (4), 830.

(14) Rauf, A.; Khalil, A. A.; Olatunde, A.; Khan, M.; Anwar, S.; Alafan, A.; Rengasamy, K. R. R. Diversity, Molecular Mechanisms and Structure-Activity Relationships of Marine Protease Inhibitors—a Review. Pharmacol. Res. 2021, 166, 105521.

(15) Cid-Galllegos, M. S.; Corzo-Ríos, L. J.; Jiménez-Martinez, C.; Sánchez-Chino, X. M. Protease Inhibitors from Plants as Therapeutic Agents- A Review. Plant Foods Hum. Nutr. (N. Y., NY, U. S.) 2022, 77 (1), 20–29.

(16) Miller, B.; Friedman, A. J.; Choi, H.; Hogan, J.; McCammon, J. A.; Hook, V.; Gerwick, W. H. The Marine Cyanobacterial Metabolite Gallinamide A Is a Potent and Selective Inhibitor of Human Cathepsin L. J. Nat. Prod. 2014, 77 (1), 92–99.

(17) Ashhurst, A. S.; Tang, A. H.; Fajtová, P.; Yoon, M. C.; Aggarwal, A.; Bedding, M. J.; Stoye, A.; Beretta, L.; Pwee, D.; Drellich, A.; Skinner, D.; Li, L.; Meek, T. D.; McKerrow, J. H.; Hook, V.; Tseng, C.-T.; Larance, M.; Turville, S.; Gerwick, W. H.; O’Donoghue, A. J.; Payne, R. J. Potent Anti-SARS-Cov-2 Activity by the Natural Product Gallinamide A and Analogues via Inhibition of Cathepsin L. J. Med. Chem. 2022, 65 (4), 2956–2970.

(18) Newman, D. J.; Cragg, G. M. Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019. J. Nat. Prod. 2020, 83 (3), 770–803.

(19) Yoon, M. C.; Solania, A.; Jiang, Z.; Christy, M. P.; Podvin, S.; Mosier, C.; Lietz, C. B.; Ito, G.; Gerwick, W. H.; Wolan, D. W.; Hook, G.; O’Donoghue, A. J.; Hook, V. Selective Neutral pH Inhibitor of Cathepsin B Designed Based on Cleavage Preferences at Cytosolic and Lysosomal pH Conditions. ACS Chem. Biol. 2021, 16 (9), 1628–1643.

(20) Yamamoto, A.; Tomoo, K.; Hara, T.; Murata, M.; Kitamura, K.; Ishida, T. Substrate Specificity of Bovine Cathepsin B and Its Inhibition by CA074, Based on Crystal Structure Refinement of the Complex. J. Biochem. 2000, 127 (4), 635–643.

(21) Towatari, T.; Nikawa, T.; Murata, M.; Yokoo, C.; Tamai, M.; Hanada, K.; Katunuma, N. Novel Epoxy-succinyl peptides a Selective Inhibitor of Cathepsin B in Vivo. FEBS Lett. 1991, 280 (2), 311–315.

(22) Murata, M.; Miyashita, S.; Yokoo, C.; Tamai, M.; Hanada, K.; Hatayama, K.; Towatari, T.; Nikawa, T.; Katunuma, N. Novel EPOXYSUCCINYL Peptides Selective Inhibitors of Cathepsin B in Vitro. FEBS Lett. 1991, 280 (2), 307–310.

(23) Ni, J.; Lan, F.; Xu, Y.; Nakanishi, H.; Li, X. Extralysosomal Cathepsin B in Central Nervous System: Mechanisms and Therapeutic Implications. Brain Pathol. 2022, e13071.

(24) Yoon, M. C.; Christy, M. P.; Phan, V. V.; Gerwick, W. H.; Hook, G.; O’Donoghue, A. J.; Hook, V. Molecular Features of CA074 pH-Dependent Inhibition of Cathepsin B. Biochemistry 2022, 61 (4), 228–238.

(25) Barrett, A. J.; Kembhavi, A. A.; Brown, M. A.; Kirschke, H.; Knight, C. G.; Tamai, M.; Hanada, K. L-Trans-Epoxy-succinyl-Leucylamido(4-Guanidino)Butane (E-64) and Its Analogues as Inhibitors of Cysteine Proteinases Including Cathepsins B, H and L. Biochem. J. 1982, 201 (1), 189–198.

(26) Voet, D.; Voet, J. In Biochemistry, 2nd ed.; John Wiley & Sons: New York, NY, 1995; pp 482–485.